Long-acting beta2-agonists are bronchodilators, a class of asthma
medication, taken on a daily basis to relax the smooth muscle lining
of bronchial tubes, the airways that carry air to the lungs. It
allows the tubes to stay open for a longer period of time to help
breathe easily. Long acting beta2-agonists are used to open narrow
airways and prevent asthma attacks. These are used in dry powder or
metered-dose inhalers. According to the FDA guidelines, long acting
beta2-agonists should not be used without being combined with inhaled
corticosteroid. Examples of inhaled steroids are Qvar, Flovent,
Budesonide, Azmacort, Asmanex, and Aerobid. The most commonly
prescribed long acting beta2-agonists are Salmeterol (Serevent),
Formoterol (Foradil and Perforomist), and Arformoterol (Brovana).
Report Overview @
https://www.transparencymarketresearch.com/long-acting-beta2agonists-drugs-market.html
Long acting beta2-agonists are considered primary drugs of choice to
control chronic asthma and chronic obstructive pulmonary disease
(COPD), as these make breathing easier. The usage of long acting
beta2-agonists in adults with persistent asthma results in improved
lung function. Increasing the dose of inhaled corticosteroids results
in less use of quick-relief medicines and improves lung function and
symptoms.
Ability of the drug to control asthma and rise in the population
suffering from asthma and chronic diseases such as COPD are expected
to drive the global long acting beta2-agonists drugs market.
According to the World Health organization (WHO), in 2015, nearly
383,000 people died due to asthma. Many asthma-related deaths occur
in low- and lower-middle income countries. It also stated that
approximately 235 million people are presently suffering from asthma
and it is a common disease among children.
Moreover, in 2015, chronic obstructive pulmonary disease accounted
for 3 million deaths across the world, approximately 5% of all the
deaths. The primary cause of chronic obstructive pulmonary disease is
exposure to tobacco smoke, either passive or active. The market is
expected to expand due to popularity of and preference for long
acting beta2-agonists drugs. However, patent and exclusivity expiry
of top selling drugs such as Serevent is likely to restrain the
global market. The global long acting beta2-agonists drugs market can
be segmented based on application, distribution channel, and region.
In terms of application, the market can be categorized into asthma
and chronic obstructive pulmonary disease (COPD). Based on
distribution channel, the global long acting beta2-agonists drugs
market can be classified into hospital pharmacies, retail pharmacies,
and online pharmacies.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33878
Geographically, the global long acting beta2-agonists drugs market
can be segmented into Asia Pacific, Latin America, Europe, North
America, and Middle East & Africa. North America held the largest
market share in 2016 owing to increase in prevalence of asthma and
chronic obstructive pulmonary disease. COPD is the third leading
cause of death in the U.S. According to the Centers for Disease
Control and Prevention (CDC), nearly 6.4% i.e., 15.7 million, people
in the U.S. reported that they had been diagnosed with chronic
obstructive pulmonary disease. CDC also stated that nearly 18.4
million people, 7.6% of the total population, aged 18 years and above
in the U.S. currently suffer from asthma. Europe accounted for the
second largest market share in 2016 owing to increase in prevalence
of asthma. According to Asthma U.K., nearly 5.4 million people in the
U.K., 1.1 million children (1 in 11) and 4.3 million adults (1 in
12), are currently diagnosed with asthma. The market in Asia Pacific,
Latin America, and Middle East & Africa is anticipated to expand
during the forecast period owing to increasing population and air
pollution.
Key players operating in the global long acting beta2-agonists drugs
market include AstraZeneca, Teva Pharmaceutical Industries Ltd.,
Bayer AG, Actelion Pharmaceuticals US, Inc. Boehringer Ingelheim
GmbH, F. Hoffmann-La Roche Ltd., and GlaxoSmithKline plc.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33878
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment